Related references
Note: Only part of the references are listed.Molecular diagnostic tests to predict the risk of progressive multifocal leukoencephalopathy in natalizumab-treated multiple sclerosis patients
Francesca Rossi et al.
MOLECULAR AND CELLULAR PROBES (2015)
Biologics in the management of ulcerative colitis - comparative safety and efficacy of TNF-α antagonists
Rebecca Fausel et al.
THERAPEUTICS AND CLINICAL RISK MANAGEMENT (2015)
Targets for new immunomodulation strategies in inflammatory bowel disease
Giovanni Monteleone et al.
AUTOIMMUNITY REVIEWS (2014)
Innate and adaptive immunity in inflammatory bowel disease
Alessandra Geremia et al.
AUTOIMMUNITY REVIEWS (2014)
Diagnosis and classification of Crohn's disease
Martin W. Laass et al.
AUTOIMMUNITY REVIEWS (2014)
Association Between Pharmacokinetics of Adalimumab and Mucosal Healing in Patients With Inflammatory Bowel Diseases
Xavier Roblin et al.
CLINICAL GASTROENTEROLOGY AND HEPATOLOGY (2014)
Dose optimization is effective in ulcerative colitis patients losing response to infliximab: A collaborative multicentre retrospective study
Monica Cesarini et al.
DIGESTIVE AND LIVER DISEASE (2014)
Biosimilars in the therapy of inflammatory bowel diseases
Tibor Hlavaty et al.
EUROPEAN JOURNAL OF GASTROENTEROLOGY & HEPATOLOGY (2014)
New biologic therapeutics for ulcerative colitis and Crohn's disease
Shilan Mozaffari et al.
EXPERT OPINION ON BIOLOGICAL THERAPY (2014)
Development of Drugs to Target Interactions Between Leukocytes and Endothelial Cells and Treatment Algorithms for Inflammatory Bowel Diseases
Silvio Danese et al.
GASTROENTEROLOGY (2014)
Subcutaneous Golimumab Induces Clinical Response and Remission in Patients With Moderate-to-Severe Ulcerative Colitis
William J. Sandborn et al.
GASTROENTEROLOGY (2014)
Methotrexate in Combination With Infliximab Is No More Effective Than Infliximab Alone in Patients With Crohn's Disease
Brian G. Feagan et al.
GASTROENTEROLOGY (2014)
Subcutaneous Golimumab Maintains Clinical Response in Patients With Moderate-to-Severe Ulcerative Colitis
William J. Sandborn et al.
GASTROENTEROLOGY (2014)
Future directions in inflammatory bowel disease management
Geert R. D'Haens et al.
JOURNAL OF CROHNS & COLITIS (2014)
Etrolizumab as induction therapy for ulcerative colitis: a randomised, controlled, phase 2 trial
Severine Vermeire et al.
LANCET (2014)
TH9 cells that express the transcription factor PU.1 drive T cell-mediated colitis via IL-9 receptor signaling in intestinal epithelial cells
Katharina Gerlach et al.
NATURE IMMUNOLOGY (2014)
Natural history and long-term clinical course of Crohn's disease
Hugh James Freeman
WORLD JOURNAL OF GASTROENTEROLOGY (2014)
Performance of the Montreal classification for inflammatory bowel diseases
Lieke M. Spekhorst et al.
WORLD JOURNAL OF GASTROENTEROLOGY (2014)
Incidences of Serious Infections and Tuberculosis among Patients Receiving Anti-Tumor Necrosis Factor-α Therapy
In Kyung Yoo et al.
YONSEI MEDICAL JOURNAL (2014)
Current and emerging maintenance therapies for ulcerative colitis
Anthony O'Connor et al.
EXPERT REVIEW OF GASTROENTEROLOGY & HEPATOLOGY (2014)
A guide to prepare patients with inflammatory bowel diseases for anti-TNF-α therapy
Adérson Omar Mourão Cintra Damião
MEDICAL SCIENCE MONITOR (2014)
Diagnosis and Treatment of Latent Tuberculosis Infection in Patients with Inflammatory Bowel Diseases due to Initiation of Anti-Tumor Necrosis Factor Therapy
Tae Sun Shim
INTESTINAL RESEARCH (2014)
Methotrexate for induction of remission in refractory Crohn's disease
John W. D. McDonald et al.
COCHRANE DATABASE OF SYSTEMATIC REVIEWS (2014)
Cytokines in inflammatory bowel disease
Markus F. Neurath
NATURE REVIEWS IMMUNOLOGY (2014)
Review article: immunogenicity of anti-TNF biologics in IBD - the role of patient, product and prescriber factors
A. C. Moss et al.
ALIMENTARY PHARMACOLOGY & THERAPEUTICS (2013)
Meta-analysis using individual patient data: efficacy and durability of topical alicaforsen for the treatment of active ulcerative colitis
S. Vegter et al.
ALIMENTARY PHARMACOLOGY & THERAPEUTICS (2013)
Impact of Antibodies to Infliximab on Clinical Outcomes and Serum Infliximab Levels in Patients With Inflammatory Bowel Disease (IBD): A Meta-Analysis
Kavinderjit S. Nanda et al.
AMERICAN JOURNAL OF GASTROENTEROLOGY (2013)
Adalimumab: A Review of Its Use in the Treatment of Patients with Ulcerative Colitis
Celeste B. Burness et al.
BIODRUGS (2013)
Crohn's disease: A review of treatment options and current research
Sean Bandzar et al.
CELLULAR IMMUNOLOGY (2013)
Janus Kinase Inhibition with Tofacitinib: Changing the Face of Inflammatory Bowel Disease Treatment
Lucine Vuitton et al.
CURRENT DRUG TARGETS (2013)
Regulatory cell populations in the intestinal mucosa
Wendy A. Goodman et al.
CURRENT OPINION IN GASTROENTEROLOGY (2013)
A randomised phase I study of etrolizumab (rhuMAb β7) in moderate to severe ulcerative colitis
Paul J. Rutgeerts et al.
GUT (2013)
Adherence to Anti-TNF Therapy in Inflammatory Bowel Diseases: A Systematic Review
Anthony Lopez et al.
INFLAMMATORY BOWEL DISEASES (2013)
Tuberculosis in anti-TNF-α treated patients remains a problem in countries with an intermediate incidence: Analysis of 25 patients matched with a control population
Cândida Abreu et al.
Journal of Crohns & Colitis (2013)
ECCO position statement: The use of biosimilar medicines in the treatment of inflammatory bowel disease (IBD)
Silvio Danese et al.
JOURNAL OF CROHNS & COLITIS (2013)
IBD Golimumab in ulcerative colitis: a 'menage a trois' of drugs
Silvio Danese
NATURE REVIEWS GASTROENTEROLOGY & HEPATOLOGY (2013)
Immunogenicity of anti-TNF biologic therapies for rheumatoid arthritis
Pauline A. van Schouwenburg et al.
NATURE REVIEWS RHEUMATOLOGY (2013)
Vedolizumab as Induction and Maintenance Therapy for Ulcerative Colitis
Brian G. Feagan et al.
NEW ENGLAND JOURNAL OF MEDICINE (2013)
Vedolizumab as Induction and Maintenance Therapy for Crohn's Disease
William J. Sandborn et al.
NEW ENGLAND JOURNAL OF MEDICINE (2013)
Efficacy and mode of action of mesalazine in the treatment of diarrhoea-predominant irritable bowel syndrome (IBS-D): study protocol for a randomised controlled trial
Matthew P. Leighton et al.
TRIALS (2013)
Comprehensive review: antitumor necrosis factor agents in inflammatory bowel disease and factors implicated in treatment response
Gary R. Lichtenstein
THERAPEUTIC ADVANCES IN GASTROENTEROLOGY (2013)
Autophagy in infection, inflammation and immunity
Vojo Deretic et al.
NATURE REVIEWS IMMUNOLOGY (2013)
Immunogenicity in Biologic Therapy: Implications for Dermatology
J. M. Carrascosa
ACTAS DERMO-SIFILIOGRAFICAS (2013)
Immunogenicity to Biologics: Mechanisms, Prediction and Reduction
Swaminathan Sethu et al.
ARCHIVUM IMMUNOLOGIAE ET THERAPIAE EXPERIMENTALIS (2012)
Basis of CTLA-4 function in regulatory and conventional CD4+ T cells
Xuguang Tai et al.
BLOOD (2012)
Tolerance and Inflammation at the Gut Mucosa
Ana Maria C. Faria et al.
CLINICAL & DEVELOPMENTAL IMMUNOLOGY (2012)
Th17-Related Cytokines in Inflammatory Bowel Diseases: Friends or Foes?
I. Monteleone et al.
CURRENT MOLECULAR MEDICINE (2012)
The use of biologic agents in pediatric inflammatory bowel disease
Linda S. Yang et al.
CURRENT OPINION IN PEDIATRICS (2012)
A review and expert opinion of the use of certolizumab for Crohn's disease
Ashley T. Evans et al.
EXPERT OPINION ON BIOLOGICAL THERAPY (2012)
Dead on Arrival: Understanding the Failure of CTLA4-Immunoglobulin Therapy in Inflammatory Bowel Disease
Lloyd Mayer et al.
GASTROENTEROLOGY (2012)
Adalimumab Induces and Maintains Clinical Remission in Patients With Moderate-to-Severe Ulcerative Colitis
William J. Sandborn et al.
GASTROENTEROLOGY (2012)
Increasing Incidence and Prevalence of the Inflammatory Bowel Diseases With Time, Based on Systematic Review
Natalie A. Molodecky et al.
GASTROENTEROLOGY (2012)
Vedolizumab for the treatment of active ulcerative colitis: A randomized controlled phase 2 dose-ranging study
Asit Parikh et al.
INFLAMMATORY BOWEL DISEASES (2012)
Morphologic and immunohistochemical characterization of granulomas in the nucleotide oligomerization domain 2-related disorders Blau syndrome and Crohn disease
Carl E. I. Janssen et al.
JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY (2012)
Ustekinumab Induction and Maintenance Therapy in Refractory Crohn's Disease
William J. Sandborn et al.
NEW ENGLAND JOURNAL OF MEDICINE (2012)
Intestinal CX3C chemokine receptor 1high (CX3CR1high) myeloid cells prevent T-cell-dependent colitis
Hisako Kayama et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2012)
Changes of the cytokine profile in inflammatory bowel diseases
Gyoergyi Muzes et al.
WORLD JOURNAL OF GASTROENTEROLOGY (2012)
Screening of Budesonide Nanoformulations for Treatment of Inflammatory Bowel Disease in an Inflamed 3D Cell-Culture Model
Fransisca Leonard et al.
ALTEX-ALTERNATIVES TO ANIMAL EXPERIMENTATION (2012)
The IL-23/IL-17 pathway in inflammatory bowel disease
Alessandra Geremia et al.
EXPERT REVIEW OF GASTROENTEROLOGY & HEPATOLOGY (2012)
Oral 5-aminosalicylic acid for induction of remission in ulcerative colitis
Brian G. Feagan et al.
COCHRANE DATABASE OF SYSTEMATIC REVIEWS (2012)
Mucosal Gene Expression of Cell Adhesion Molecules, Chemokines, and Chemokine Receptors in Patients With Inflammatory Bowel Disease Before and After Infliximab Treatment
Ingrid Arijs et al.
AMERICAN JOURNAL OF GASTROENTEROLOGY (2011)
Efficacy and safety of adalimumab in Canadian patients with moderate to severe Crohn's disease: Results of the Adalimumab in Canadian SubjeCts with ModErate to Severe Crohn's DiseaSe (ACCESS) trial
Remo Panaccione et al.
CANADIAN JOURNAL OF GASTROENTEROLOGY (2011)
Autoantibodies to GP2, the major zymogen granule membrane glycoprotein, are new markers in Crohn's disease
Dirk Roggenbuck et al.
CLINICA CHIMICA ACTA (2011)
Epidemiology and Natural History of Inflammatory Bowel Diseases
Jacques Cosnes et al.
GASTROENTEROLOGY (2011)
A systematic review and economic evaluation of the use of tumour necrosis factor-alpha (TNF-α) inhibitors, adalimumab and infliximab, for Crohn's disease
J. Dretzke et al.
HEALTH TECHNOLOGY ASSESSMENT (2011)
Targeting leukocyte migration and adhesion in Crohn’s disease and ulcerative colitis
Saskia Thomas et al.
INFLAMMOPHARMACOLOGY (2011)
Increased Response and Remission Rates in Short-Duration Crohn's Disease With Subcutaneous Certolizumab Pegol: An Analysis of PRECiSE 2 Randomized Maintenance Trial Data
Stefan Schreiber et al.
AMERICAN JOURNAL OF GASTROENTEROLOGY (2010)
Certolizumab Pegol in Patients With Moderate to Severe Crohn's Disease and Secondary Failure to Infliximab
William J. Sandborn et al.
CLINICAL GASTROENTEROLOGY AND HEPATOLOGY (2010)
NOD2-associated diseases: Bridging innate immunity and autoinflammation
Arturo Borzutzky et al.
CLINICAL IMMUNOLOGY (2010)
Appropriateness of Crohn's Disease Therapy in Gastroenterological Rehabilitation
Christoph Reichel et al.
DIGESTION (2010)
Identification of complement C3 as an autoantigen in inflammatory bowel disease
Brita Ardesjo Lundgren et al.
EUROPEAN JOURNAL OF GASTROENTEROLOGY & HEPATOLOGY (2010)
Use of immunomodulators and biologic therapies in children with inflammatory bowel disease
Athos Bousvaros
EXPERT REVIEW OF CLINICAL IMMUNOLOGY (2010)
Role of Transforming Growth Factor-β in Inflammatory Bowel Disease and Colitis-associated Colon Cancer
Linda A. Feagins
INFLAMMATORY BOWEL DISEASES (2010)
Fontolizumab in Moderate to Severe Crohn's Disease: A Phase 2, Randomized, Double-blind, Placebo-controlled, Multiple-dose Study
Walter Reinisch et al.
INFLAMMATORY BOWEL DISEASES (2010)
Inflammatory Bowel Disease Developing in Paediatric and Adult Age
Graziella Guariso et al.
JOURNAL OF PEDIATRIC GASTROENTEROLOGY AND NUTRITION (2010)
Biologic Therapies Against Inflammatory Bowel Disease: A Dysregulated Immune System and the Cross Talk with Gastrointestinal Mucosa Hold the Key
Poonam Dharmani et al.
Current Molecular Pharmacology (2010)
Biological Therapies for Inflammatory Bowel Diseases
Paul Rutgeerts et al.
GASTROENTEROLOGY (2009)
Inflammatory bowel disease
Mahnaz Fatahzadeh
ORAL SURGERY ORAL MEDICINE ORAL PATHOLOGY ORAL RADIOLOGY AND ENDODONTOLOGY (2009)
Adalimumab in ulcerative colitis: Two cases of mucosal healing and clinical response at two years
Manuel Barreiro-de Acosta et al.
WORLD JOURNAL OF GASTROENTEROLOGY (2009)
Potential role of Th17 cells in the pathogenesis of inflammatory bowel disease
Zhan-Ju Liu et al.
WORLD JOURNAL OF GASTROENTEROLOGY (2009)
Successful use of adalimumab for treating fistulizing Crohn's disease with pyoderma gangrenosum: Two birds with one stone
Eva Zold et al.
WORLD JOURNAL OF GASTROENTEROLOGY (2009)
Selecting appropriate anti-TNF agents in inflammatory bowel disease
Laura Yun et al.
Expert Review of Gastroenterology & Hepatology (2009)
Efficacy and safety of tumor necrosis factor antagonists in Crohn's disease: Meta-analysis of placebo-controlled trials
Laurent Peyrin-Biroulet et al.
CLINICAL GASTROENTEROLOGY AND HEPATOLOGY (2008)
A randomized trial of ustekinumab, a human interleukin-12/23 monoclonal antibody, in patients with moderate-to-severe Crohn's disease
William J. Sandborn et al.
GASTROENTEROLOGY (2008)
IL23 differentially regulates the Th1/Th17 balance in ulcerative colitis and Crohn's disease
T. Kobayashi et al.
GUT (2008)
TGF-β1 and Smad7 in the regulation of IBD
G. Monteleone et al.
MUCOSAL IMMUNOLOGY (2008)
Current view of the immunopathagenesis in inflammatory bowel disease and its implications fair therapy
M. I. Torres et al.
WORLD JOURNAL OF GASTROENTEROLOGY (2008)
The genetics and immunopathogenesis of inflammatory bowel disease
Judy H. Cho
NATURE REVIEWS IMMUNOLOGY (2008)
The management of steroid dependency in ulcerative colitis
G. Bianchi Porro et al.
ALIMENTARY PHARMACOLOGY & THERAPEUTICS (2007)
New onset of atrial fibrillation after introduction of azathioprine in ulcerative colitis: case report and review of the literature
Andrea Cassinotti et al.
EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY (2007)
Risks and benefits of combining immunosuppressives and biological agents in inflammatory bowel disease: is the synergy worth the risk?
Stephen B. Hanauer
GUT (2007)
Interferon-gamma is causatively involved in experimental inflammatory bowel disease in mice
R. Ito et al.
CLINICAL AND EXPERIMENTAL IMMUNOLOGY (2006)
Onercept for moderate-to-severe Crohn's disease: A randomized, double-blind, placebo-controlled trial
Paul Rutgeerts et al.
CLINICAL GASTROENTEROLOGY AND HEPATOLOGY (2006)
A Phase II dose ranging, double-blind, placebo-controlled study of alicaforsen enema in subjects with acute exacerbation of mild to moderate left-sided ulcerative colitis
SJH Van Deventer et al.
ALIMENTARY PHARMACOLOGY & THERAPEUTICS (2006)
Review article: infliximab therapy for inflammatory bowel disease - seven years on
P Rutgeerts et al.
ALIMENTARY PHARMACOLOGY & THERAPEUTICS (2006)
Small intestinal bacterial overgrowth: Roles of antibiotics, prebiotics, and Probiotics
EMM Quigley et al.
GASTROENTEROLOGY (2006)
Randomised controlled trial of azathioprine and 5-aminosalicylic acid for treatment of steroid dependent ulcerative colitis
S Ardizzone et al.
GUT (2006)
Oral tolerance: Therapeutic implications for autoimmune diseases
Ana M. C. Faria et al.
CLINICAL & DEVELOPMENTAL IMMUNOLOGY (2006)
5-aminosalicylate use and colorectal cancer risk in inflammatory bowel disease: a large epidemiological study
TP van Staa et al.
GUT (2005)
Treatment of ulcerative colitis with a humanized antibody to the α4β7 integrin
BG Feagan et al.
NEW ENGLAND JOURNAL OF MEDICINE (2005)
NOD2 and Crohn's disease: Loss or gain of function?
L Eckmann et al.
IMMUNITY (2005)
Biologic therapy for inflammatory bowel disease
S Ardizzone et al.
DRUGS (2005)
Azathioprine and mesalamine for prevention of relapse after conservative surgery for Crohn's disease
S Ardizzone et al.
GASTROENTEROLOGY (2004)
Guidelines for the management of inflammatory bowel disease in adults
MJ Carter et al.
GUT (2004)
Chemokine receptors and leukocyte trafficking in the mucosal immune system
IR Williams
IMMUNOLOGIC RESEARCH (2004)
Severe villus atrophy and chronic malabsorption induced by azathioprine
TR Ziegler et al.
GASTROENTEROLOGY (2003)
Azathioprine: old drug, new actions
JS Maltzman et al.
JOURNAL OF CLINICAL INVESTIGATION (2003)
Chemokine expression in IBD. Mucosal chemokine expression is unselectively increased in both ulcerative colitis and Crohn's disease
C Banks et al.
JOURNAL OF PATHOLOGY (2003)
The immune system: a target for functional foods?
PC Calder et al.
BRITISH JOURNAL OF NUTRITION (2002)
The role of Th1/Th2 polarization in mucosal immunity
MF Neurath et al.
NATURE MEDICINE (2002)
The immunology of inflammatory bowel disease
S Plevy
GASTROENTEROLOGY CLINICS OF NORTH AMERICA (2002)
Etanercept for active Crohn's disease: A randomized, double-blind, placebo-controlled trial
WJ Sandborn et al.
GASTROENTEROLOGY (2001)
Infliximab in the treatment of severe, steroid-refractory ulcerative colitis: A pilot study
BE Sands et al.
INFLAMMATORY BOWEL DISEASES (2001)
Share Paper
